Skip to main content
SpringerLink
Log in

Tumeurs endocrines gastro-entéro-pancréatiques (TE GEP). Classifications, présentations cliniques, marqueurs biologiques

  • Chapter
Tumeurs endocrines thoraciques et digestives

  • 339 Accesses

Abstrait

Ce chapitre fait le point sur les classifications, les modalités du diagnostic clinique, le bilan biologique des tumeurs endocrines gastro-entéro-pancréatiques (TE GEP) non à petites cellules (1–5). Nous utiliserons le terme de «tumeur endocrine», pour définir des tumeurs bénignes ou malignes. Ce terme est consacré par la dernière classification OMS 2000 des tumeurs digestives, même s’il n’est pas reconnu par la dernière classification OMS 2004 des tumeurs pulmonaires et thymiques (6–8). Le terme «carcinoïde» se référera aux tumeurs bien différenciées. Le terme carcinome sera employé pour définir les tumeurs malignes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Baudin E (2007) Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab 3: 228–39

    Article  PubMed  CAS  Google Scholar 

  2. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934–59

    Article  PubMed  Google Scholar 

  3. Quaedvlieg PF, Visser O, Lamers CB et al. (2001) Epdidemiology and survival in patients with carcinoid disease in the Netherlands: an epidemiological study with 2391 patients. Ann Oncol 12: 1295–300

    Article  PubMed  CAS  Google Scholar 

  4. Hemminki K, Li X (2001) Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 94: 444–8

    Article  PubMed  CAS  Google Scholar 

  5. Skuladottir H, Hirsch FR, Hansen HH et al. (2002) Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-bases study in Denmark. Lung Cancer 37: 127–35

    Article  PubMed  Google Scholar 

  6. Solcia E, Klöppel G, Sobin LH (2000) Histological typing of endocrine tumors. World Health Organisation International Histological Classification of Tumors. Springer, Berlin

    Google Scholar 

  7. Travis WD, Brambilla E, Müller-Hermelink, Harris C (2004) Pathology of the lung, pleura, thymus and heart. IARC Press, Lyon

    Google Scholar 

  8. Heitz P, Komminoth P, Perren A et al. (2004) Tumours of endocrine organs. World Health Organisation Classification of Tumors International Agency for Research on Cancer. IARC Press, Lyon.

    Google Scholar 

  9. Helpap B, Köllermann J (2001) Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence? Virchows Arch 438: 86–91

    Article  PubMed  CAS  Google Scholar 

  10. Soga J (2003) Carcinoid and their variant endocrinomas. An analysis of 11,842 reported cases. J Exp Clin Cancer Res 22: 517–30

    PubMed  CAS  Google Scholar 

  11. Travis WD, Rush W, Flieder DB et al. (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22: 934–44

    Article  PubMed  CAS  Google Scholar 

  12. Moran CA, Suster S (2000) Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathological analysis of 80 cases. Am J Clin Pathol 114: 100–10

    Article  PubMed  CAS  Google Scholar 

  13. Mitry E, Baudin E, Ducreux M et al. (1999) Treatment of poorly-differentiated neuroendocrine tumours with etoposide and cisplatine Br J Cancer 81(8): 1351–5

    Article  PubMed  CAS  Google Scholar 

  14. Garcia-Yuste M, Matilla JM, Alvarez-Gago T et al. and the EMETNE-SEPRA (2000) Prognostic factors in neuroendocrine lung tumors: a spanish multicenter study. Ann Thorac Surg 70: 258–63

    Article  PubMed  CAS  Google Scholar 

  15. Takei H, Asamura H, Maeshima A et al. (2002) Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124: 285–92

    Article  PubMed  Google Scholar 

  16. Cardillo G, Dstat FS, Di Martino M et al. (2004) Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thor Surg 77(5): 1781–5

    Article  Google Scholar 

  17. Stinner B, Kisker O, Zielke A et al. (1996) Surgical management of carcinoid tumors of small bowel, appendix, colon, and rectum. W J Surg 20: 183–8

    Article  CAS  Google Scholar 

  18. Schindl M, Niederle B, Häfner M et al. (1998) Stage dependant therapy of rectal carcinoid tumors. W J Surg 22: 628–34

    Article  CAS  Google Scholar 

  19. Lowney JK, Frisella MM, Lairmore TC et al. (1999) Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary size. Surgery 125: 1043–9

    Google Scholar 

  20. Onaitis MW, Kirshbom PM, Hayward TZ et al. (2000) Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 232: 549–56

    Article  PubMed  CAS  Google Scholar 

  21. Shebani KO, Souba WW, Finkelstein DM et al. (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 29: 815–23

    Article  Google Scholar 

  22. Rindi G, Azzoni C, La Rosa S et al. (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis Gastroenterology 116: 532–42

    Article  PubMed  CAS  Google Scholar 

  23. Gullo L, Migliori M, Falconi M et al. (2003) Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol 98: 2435–9

    Article  PubMed  Google Scholar 

  24. Hoffmann KM, Furukawa M, Jensen RT (2005) Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 19: 675–97

    Article  PubMed  CAS  Google Scholar 

  25. Baudin E, Bidart JM, Rougier P et al. (1999) Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. J Clin Endocrinol Metab 84: 69–75

    Article  PubMed  CAS  Google Scholar 

  26. Pacak K, Ilias I, Chen CC et al. (2004) The role of 18F-fluorodeoxyglucose positron emission tomography and 111I-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome. J Clin Endocrinol Metab 89: 2214–21

    Article  PubMed  CAS  Google Scholar 

  27. Leboulleux S, Baudin E, Young J et al. (1999) Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. Eur J Endocrinol 140: 187–91

    Article  PubMed  CAS  Google Scholar 

  28. Sturm N, Lantuejoul S, Laverriere MH et al. (2003) Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34bE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 32: 918–25

    Article  Google Scholar 

  29. Norheim I, Oberg K, Theodorsson-Norheim E et al. (1987) Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localisation, hormone production, and survival. Ann Surg 206: 115–25

    Article  PubMed  CAS  Google Scholar 

  30. O’Connor Dt, Deftos LJ (1986) Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314: 1145–51

    PubMed  CAS  Google Scholar 

  31. Baudin E, Dromain C (2002) Biology and imaging of neuroendocrine tumors Rev Prat 52: 268–73

    PubMed  Google Scholar 

  32. Taupenot L, Harper KL, O’Connor DT (2003) The chromogranin-secretogranin family. N Engl J Med 348: 1134–49

    Article  PubMed  CAS  Google Scholar 

  33. Janson ET, Holmberg L, Stridsberg M et al. (1997) Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8: 685–90

    Article  PubMed  CAS  Google Scholar 

  34. Nobels FR, Wekkeboom DJ, Coopmans W et al. (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the a-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82: 2622–8

    Article  PubMed  CAS  Google Scholar 

  35. Baudin E, Gigliotti A, Ducreux M et al. (1998) Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78: 1102–7

    PubMed  CAS  Google Scholar 

  36. Bajetta E, Ferrari L, Martineti A et al. (1998) Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyndole acetic acid evaluation in patients with neuroendocrine tumors. Br J Cancer 86: 858–65

    Google Scholar 

  37. Nehar D, Lombard-Bohas C, Olivieri S et al. (2004) Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endoc 60: 644–52

    Article  CAS  Google Scholar 

  38. Goebel S, Serrano J, Yu F et al. (1999) Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85: 1470–83

    Article  PubMed  CAS  Google Scholar 

  39. Stivanello M, Berruti A, Torta M et al. (2001) Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 12: S73–S77

    Article  PubMed  Google Scholar 

  40. Stabile BE, Howard TJ, Passaro E et al. (1990) Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg 125: 451–3

    PubMed  CAS  Google Scholar 

  41. Stridsberg M, Oberg K, Li Q et al. (1995) Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144: 49–59

    Article  PubMed  CAS  Google Scholar 

  42. Baudin E, Bidart JM, Bachelot A et al. (2001) Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12: S79–S82

    Article  PubMed  Google Scholar 

  43. Degorce F, Goumon Y, Jacquemart L et al. (1999) A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145–245). Br J Cancer 79: 65–71

    Article  PubMed  CAS  Google Scholar 

  44. Bender H, Maier A, Wiedenmann B et al. (1992) Immunoluminometric assay of chromogranin A in serum with commercially available reagents. Clin Chem 38: 2267–72

    PubMed  CAS  Google Scholar 

  45. Stridsberg M, Eriksson B, Öberg K (2003) A comparison between three commercials kits for chromogranin A measurements. J Endocrinol 177: 337–41

    Article  PubMed  CAS  Google Scholar 

  46. O’Connor DT, Pandian MR, Carlton E et al. (1989) Rapid radioimmunoassay of circulating chromogranin A: In votro stability, exploration of the neuroendocrine charachter of neoplasia, and assessment of the effects of organ failure. Clin Chem 35: 1631–7

    PubMed  CAS  Google Scholar 

  47. Borch K, Stridsberg M, Burman P et al. (1997) Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 32: 198–202

    Article  PubMed  CAS  Google Scholar 

  48. Hsiao RJ, Mezger MS, O’Connor DT (1990) Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 37: 955–64

    Article  PubMed  CAS  Google Scholar 

  49. Giovanella L, Ceriani L, Lumastro C et al. (2007) False-positive serum chromogranin A assay due to heterophile antibody interference. Clin Chim Acta 379: 171–2

    Article  PubMed  CAS  Google Scholar 

  50. Eriksson B, Arnberg H, Oberg K et al. (1990) A polyclonal antiserum against chromogranin A and B—a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 122: 145–55

    PubMed  CAS  Google Scholar 

  51. Dittati R, Meo S, Gion M et al. (2004) Biological variation of plasma chromogranin A. Clin Chem Lab Med 42: 109–10

    Article  Google Scholar 

  52. Eriksson B, Oberg K, Skogseid B (1989) Neuroendorine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 28: 373–7

    Article  PubMed  CAS  Google Scholar 

  53. Meijer WG, Kema IP, Volmer M et al. (2000) Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 46: 1588–96

    PubMed  CAS  Google Scholar 

  54. Panzuto F, Severi C, Canizzaro R et al. (2004) Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 27: 6–11

    PubMed  CAS  Google Scholar 

  55. Borch K, Ahren B, Ahlman H et al. (2005) Gastric carcinoids. Biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242: 64–73

    Article  PubMed  Google Scholar 

  56. Brandi ML, Gagel RF, Angeli A et al. (2001). Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endoc Metab 86(12): 5658–71

    Article  CAS  Google Scholar 

  57. Hammel P, Vilgrain V, Terris B et al. (2000) Gastroenterology 119(4): 1087–95

    Article  PubMed  CAS  Google Scholar 

  58. Grandberg D Stridsberg M, Seensalu R et al. (1999) Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 84(8): 2712–7

    Article  Google Scholar 

  59. Bashir S, Gibril F, Ojeaburu JV et al. (2002) Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids patients with gastrinomas. Aliment Pharmacol Ther 16(7): 1367–82

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Médecine nucléaire et oncologie endocrinienne, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805, Villejuif Cedex

    É. Baudin

  2. Service de gastro-entéologie Déartement de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, France

    M. Ducreux

  3. département de cancérologie, Hôpital universitaire Paul-Brousse, Rue P.Vaillant-Couturier, 94805, Villejuif Cedex

    M. Ducreux

  4. Clinique Marc Linquette, CHRU de Lille, Rue du Pr. Laguesse, 59037, Lille Cedex

    M. d’Herbomez

Authors
  1. É. Baudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ducreux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. d’Herbomez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Baudin, É., Ducreux, M., d’Herbomez, M. (2008). Tumeurs endocrines gastro-entéro-pancréatiques (TE GEP). Classifications, présentations cliniques, marqueurs biologiques. In: Tumeurs endocrines thoraciques et digestives. Springer, Paris. https://doi.org/10.1007/978-2-287-35574-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-35574-5_3

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-35573-8

  • Online ISBN: 978-2-287-35574-5

Publish with us

Policies and ethics

Search

Navigation